Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FD1BA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 5, 2025, for the supply of Xtandi 80 mg tablets in quantities of 60 units. The contract is valued at $4,169.59 under a firm fixed-price arrangement with an ultimate completion date of September 8, 2025. This delivery order does not utilize a set-aside designation and represents performance at the contractor's Park Ridge, Illinois facility. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide.
Xtandi (enzalutamide) is an oral androgen receptor inhibitor used in the treatment of prostate cancer, reflecting the broader oncology medication portfolio that DMS Pharmaceutical Group supplies to military health facilities. As a critical supplier within the federal pharmaceutical supply chain, the contractor has consistently demonstrated capability in delivering branded and generic prescription drugs, biologics, and specialized medical consumables to support DOD healthcare operations. This delivery order exemplifies the routine procurement activities conducted through the SPE2DB program to maintain pharmaceutical inventory levels across military medical treatment facilities.
Quick answers
Who was awarded contract SPE2DB25FD1BA?
SPE2DB25FD1BA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 5, 2025.
How much is contract SPE2DB25FD1BA worth?
The government has obligated $4,170 on SPE2DB25FD1BA.
Is contract SPE2DB25FD1BA an order under another contract?
Yes. SPE2DB25FD1BA is a delivery order under SPE2DB20D9226, an indefinite delivery contract.
Was contract SPE2DB25FD1BA competed?
The extent of competition for SPE2DB25FD1BA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award